Nomura Research in a Jan 15 research report says: “In our view, the key focus in Biosensor’s (BIG) upcoming quarterly results should be sequential growth of its DES revenue; in the absence of new geographical launches, we believe q-o-q growth of above 10% should reaffirm the traction its flagship BioMatrix is garnering in existing markets.
Biosensors International Group rated buy
written by Editor on January 19th, 2010 |
No Comments
Font size:
